ABSTRACT
INTRODUCTION
With over 90% of all Americans being managed for diabetes by their primary care physicians States were attributed to diabetes-related illnesses. 2 Although there is general agreement among patients and practitioners that PCPs are overworked and undercompensated, the desire to become more adept at managing diabetes appears to be becoming a popular trend.
In some communities, a patient may wait 3 months or longer before they have their initial consultation visit with an endocrinologist. Out of necessity, more community-based PCPs have become as proficient at initiating and titrating insulin as their referral sources, thus allowing patients to receive timely and aggressive diabetes management. Improvement in economic and medical end-points can be achieved with even modest reductions in glycated hemoglobin (HbA 1c ). This article will discuss ways by which intensive insulin therapy can be rationally introduced to patients in busy primary care practices, many of which do not have access to certified diabetic educators, nurse practitioners, or physician assistants. In these practices, the physician alone may be the designer, presenter, and educator for a given intensification regimen.
These treatment protocols can be introduced in a rapid and efficient manner allowing the physician to move quickly to their next patient. 
PHYSIOLOGIC INSULIN-REPLACEMENT THERAPY OVERVIEW

Basal Insulin Intensification Protocols
The American Diabetes Association consensus statement for managing hyperglycemia recommends that basal insulin be initiated if a patient is symptomatic or has an HbA 1c >8.5% while using metformin in conjunction with lifestyle intervention. 6 Several recently published studies have demonstrated the safety and efficacy of patient-directed basal insulin algorithms.
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The primary objective of the AT.LANTUS trial (A Trial Comparing Lantus Algorithms to Achieve
Normal Blood Glucose Targets in Subjects With
Uncontrolled Blood Sugar) was to compare the safety and efficacy of insulin adjustments. Over a period of 26 weeks, 4500 patients were given insulin glargine (Lantus) once daily. 13 Half the patients were randomized to clinic-based weekly dose adjustments based upon the average blood glucose levels taken 3 days prior to the week's end as shown in Table 2 . 13 In AT.LANTUS the incidence of nocturnal, severe, and symptomatic hypoglycemia were not statistically significant between the two groups of patients. In the patient-led titration algorithm, the fasting blood sugar levels (achieved by the patients) were lower than those in the physician-led titration algorithm. This was also evidenced with a higher dose of insulin that was used in the patient- Table 1 . Strategies for initiating and titrating insulin for treatment-naive patients with type 2 diabetes.
• Suggest that insulin will help patient achieve glycemic targets and minimize the risk of long-term complications.
• Allow patients to actively participate in their insulin dose titration.
• Always praise patients on insulin for their efforts at achieving their glycemic targets at their visits. Remember, patients who are using insulin do not have normal functioning pancreases. They are calculating their doses of insulin, themselves, perhaps multiple times each day. Insulin prescribers should do everything possible to help them become successful in insulin dosing.
• Individualize therapy to meet the needs of each patient. Determine which treatment algorithm might work best for every patient.
• Enforce and emphasize the importance of lifestyle intervention. This should minimize weight gain and reduce postprandial glucose excursions.
• Consider having group office visits run in conjunction with a certified diabetic educator. Often 8-20 patients can be seen at these group visits, which are time efficient and reimbursable by third party payers.
• Provide each patient with an individualized written insulin protocol to which they can refer to.
• Prescribe insulin pen devices whenever possible. Dose titration of insulin is much more accurate with pens than with vials and syringes.
• Teach patients on the importance of identifying and appropriately managing hypoglycemic events.
• When initiating basal insulin use 0.4 units/kg/day as your starting dose. Continue metformin if possible.
• If patient requires more than 60 units of basal insulin per day and their HbA 1c is >7%, add a rapid acting insulin analog to the largest meal of the day. The dose for the rapid acting insulin is 0.1 units/kg per meal.
• If HbA 1c is not reduced to target after 3 months of basal plus bolus, add a second injection at the next largest meal of the day. Repeat the HbA 1c at 3 months and if still above target add a third mealtime injection.
• Patients on basal bolus insulin therapy should consider modified paired glucose testing in order to fine-tune their treatment regimen.
HbA 1c =glycated hemoglobin.
randomized to the insulin glargine group were initiated on 10 units of insulin to be taken at a consistent time each evening before bedtime.
Fasting glucose levels were checked daily. • Initial dose insulin glargine 10 units at bedtime. Adjust weekly.
• Measurements used to calculate dose adjustments were monitored 3 days prior to dose titration.
• No increase in dose permitted if any blood glucose reading is <72 mg/dL.
(B)
• Initial dose glargine 10 units at bedtime.
• Self-titrate two units every 3 days to target fasting blood glucose <100 mg/dL (equivalent to the highest FBG value over the previous 7 days).
cohort demonstrated slightly higher rates of nocturnal hypoglycemia. individuals with type 2 diabetes who were on dual oral agent therapy were randomized into this study. They were randomized into the three groups. One group was randomized to biphasic insulin aspart 70/30 twice daily. The second group was randomized to prandial insulin, aspart, three times daily. The third randomization was using basal insulin detemir once daily at bedtime.
The trial used a clinically relevant protocol with clinic visits every 3 months, a schedule similar to that routinely followed in the primary care >6.5% at the end of year 1) were eligible for intensification of their insulin regimens.
Therapy with sulfonylurea was replaced with an additional type of rapid acting or mixed insulin regimen as follows: (1) (1) regimens using biphasic or prandial insulin reduced HbA 1c to a greater extent than basal, but were to be associated with a greater risk of hypoglycemia and weight gain; (2) most patients are likely to require more than one type of insulin to achieve target HbA 1c levels over time as very few individuals were able to maintain their HbA 1c levels at <6.5%. The most important aspect of dose titration is minimization of the risk of hypoglycemia.
The PREDICTIVE 303 and TITRATE studies both demonstrated that overall and nocturnal hypoglycemia rates are minimized using the protocols shown in Tables 3 and 4. 11-14
Perhaps the easiest and safest protocol to initiate would mirror that used in the Canadian Insight Trial (Table 5) . 
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